BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 25500829)

  • 21. Textural features of
    Saleem BR; Beukinga RJ; Boellaard R; Glaudemans AW; Reijnen MM; Zeebregts CJ; Slart RH
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):886-894. PubMed ID: 28013350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III.
    Desseroit MC; Visvikis D; Tixier F; Majdoub M; Perdrisot R; Guillevin R; Cheze Le Rest C; Hatt M
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1477-85. PubMed ID: 26896298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plausibility and redundancy analysis to select FDG-PET textural features in non-small cell lung cancer.
    Pfaehler E; Mesotten L; Zhovannik I; Pieplenbosch S; Thomeer M; Vanhove K; Adriaensens P; Boellaard R
    Med Phys; 2021 Mar; 48(3):1226-1238. PubMed ID: 33368399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
    Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
    J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis.
    Deng SM; Zhang W; Zhang B; Chen YY; Li JH; Wu YW
    PLoS One; 2015; 10(6):e0129028. PubMed ID: 26038827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
    Lim R; Eaton A; Lee NY; Setton J; Ohri N; Rao S; Wong R; Fury M; Schöder H
    J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
    Zhang H; Wroblewski K; Pu Y
    Acta Radiol; 2012 Jun; 53(5):561-8. PubMed ID: 22661603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
    Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
    Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
    Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
    Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
    Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
    Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating heterogeneity of primary tumor (18)F-FDG uptake in breast cancer with a dedicated breast PET (MAMMI): a feasibility study based on correlation with PET/CT.
    Koolen BB; Vidal-Sicart S; Benlloch Baviera JM; Valdés Olmos RA
    Nucl Med Commun; 2014 May; 35(5):446-52. PubMed ID: 24686195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
    Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ
    Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of the intratumoral heterogeneity of (18) F-FDG uptake in oral cavity cancer.
    Kwon SH; Yoon JK; An YS; Shin YS; Kim CH; Lee DH; Jo KS; Lee SJ
    J Surg Oncol; 2014 Nov; 110(6):702-6. PubMed ID: 24975131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
    Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
    Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
    Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
    Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.